Drug Profile
TK 112690
Alternative Names: METREXASSISTTM; TK-112690; TK-90Latest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator Tosk
- Class Anti-inflammatories; Chemoprotectants; Pyrimidines
- Mechanism of Action Uridine phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mucositis
Most Recent Events
- 02 Jan 2023 TK 12690 is still in phase IIa development for Mucositis (Chemotherapy-induced, Prevention, In adults, In the elderly) in India (IV)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Mucositis(Combination therapy, In the elderly, Chemotherapy-induced, In adults, Prevention) in India (IV)
- 18 Oct 2019 Tosk completes enrolment in its phase II trial for Mucositis (Chemotherapy-induced, Prevention, In adults, In the elderly) in India (IV) (NCT04046250)